CervoMed’s Dementia Drug Fails Phase 2b Trial, Stock Plunges
CervoMed’s neflamapimod failed its Phase 2b dementia drug trial, causing its stock to plummet. The drug did not meet primary or secondary endpoints, raising concerns about its effectiveness in treating dementia with Lewy bodies.
CervoMed’s Dementia Drug Fails Phase 2b Trial, Stock Plunges Read More »